Clinical Trials Browser

Interventional × Immunoglobulin Light-chain Amyloidosis × 90 days × Clear all

NCT04847453 2026-03-18

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Phase 1 Recruiting

Immunoglobulin Light-chain Amyloidosis

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04512235 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT07224672 2026-03-17

ALANIS

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07081646 2026-03-13

ALACRITY

Phase 1/2 Recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT06192979 2026-03-09

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Phase NA Recruiting

Immunoglobulin Light-chain Amyloidosis

NCT01758042 2026-03-06

BMT

Phase NA Completed

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Anemia, Aplastic, Anemia, Sickle Cell, Autoimmune Diseases, Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Thalassemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Anemia, Diamond-Blackfan, Renal Insufficiency, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT06569147 2026-03-06

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Phase 1/2 Recruiting

Immunoglobulin Light-chain Amyloidosis

NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Phase 2 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT06963216 2026-02-27

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Phase 3 Recruiting

Immunoglobulin Light-chain Amyloidosis, Blood Coagulation Disorders, Factor X Deficiency, Hematologic Diseases, Hemorrhagic Disorders

NCT05145816 2026-02-17

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Phase 1/2 Recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT05898646 2026-01-13

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

Phase 2 Recruiting

Immunoglobulin Light-chain Amyloidosis

NCT07335887 2026-01-13

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis